acetylsalicylic acidWhat was measured
Measured, with no finding
323 endpoints
Show what was measuredHide what was measured
abdominal pain
unclear
Risks of abdominal pain and GERD-related symptoms were non-significantly increased in the ASA groups
PMID 21902288 · one of two readings recorded this
adverse events by daily dose
increases
More patients receiving doses >1000 mg/day reported AEs (18.1%) than those receiving doses <500 mg/day (15.1%) or those receiving placebo (13.5%)
PMID 21902288 · one of two readings recorded this
adverse events, interaction with age or sex
no effect
There was no interaction by age or sex for any of the events of interest
PMID 21902288 · one of two readings recorded this
adverse events, multiple-dose versus single-dose
increases
Multiple-dose administration of ASA (up to 5 days) was associated with an increased incidence of AEs (16.2%) when compared with single-dose administration (12.8%)
PMID 21902288 · one of two readings recorded this
adverse events, multiple-dose versus single-dose
increases
this was similar to results observed in the placebo arm (17.0% and 12.8%, respectively)
PMID 21902288 · one of two readings recorded this
cerebral hemorrhage and hypersensitivity reaction
no effect
No cerebral hemorrhage or hypersensitivity reaction occurred in any of the trials
PMID 21902288 · one of two readings recorded this
combined dyspepsia terms
no effect
No statistically significant differences for the combined terms of dyspepsia were found between treatments, although the ORs were >1.0 for the comparisons with ibuprofen
PMID 21902288 · one of two readings recorded this
GERD-related symptoms
unclear
Risks of abdominal pain and GERD-related symptoms were non-significantly increased in the ASA groups
PMID 21902288 · one of two readings recorded this
headache
decreases
There was a reduction in the risk of headache from ASA and there were non-significant increases in tinnitus and non-GI bleeding
PMID 21902288 · one of two readings recorded this
minor dyspepsia, age interaction
increases, p = 0.052
a borderline statistically significant (p = 0.052) interaction effect was observed for patients ≥40 years of age when compared with those <40 years of age (OR 1.98 [95% CI 1.2, 3.1])
PMID 21902288 · one of two readings recorded this
non-GI bleeding
unclear
There was a reduction in the risk of headache from ASA and there were non-significant increases in tinnitus and non-GI bleeding
PMID 21902288 · one of two readings recorded this
overall incidence of adverse events, risk difference
no effect
risk difference 1.0% (95 % CI −0.5, 2.5)
PMID 21902288 · one of two readings recorded this
overall incidence of adverse events
no effect
similar between subjects treated with ASA (741/4884; 15.2%) and those treated with placebo (580/3731; 15.5%).[OR 1.1; 95% CI 0.96, 1.2]
PMID 21902288 · one of two readings recorded this
patient-reported gastrointestinal adverse events and overall adverse events, MedDRA-coded, ASA versus placebo (ASA arm includes combinations with vitamin C, caffeine, calcium, pseudoephedrine, lidocaine, dextromethorphan)
no effect, 741/4884 (15.2%) with ASA versus 580/3731 (15.5%) with placebo for all AEs
Not recorded as a finding: this platform holds no node for the endpoint
The overall incidence of AEs was low, and was similar between subjects treated with ASA (741/4884; 15.2%) and those treated with placebo (580/3731; 15.5%).
PMID 21902288 · one of two readings recorded this
patient-reported gastrointestinal adverse events (MedDRA-coded, incl. dyspepsia) after short-term mostly single-dose ASA versus placebo, pooled Cochran-Mantel-Haenszel odds ratio
increases
Not recorded as a finding: this platform holds no node for the endpoint
GI AEs of any severity were more frequent in the ASA groups than in the placebo groups, as summarized in.
PMID 21902288 · one of two readings recorded this
proportion of ASA-treated patients receiving a single dose
n = 6181
Of the 6181 patients allocated to ASA and ASA combinations, 5099 (82.5%) received a single dose, 1082 (17.5%) received a multiple-dose regimen, and 188 (3.0%) were treated for more than 5 days
PMID 21902288 · one of two readings recorded this
serious GI adverse events and GI hemorrhage
no effect
There were very few serious GI adverse events
PMID 21902288 · one of two readings recorded this
severe dyspepsia
unclear
severe dyspepsia was non-significantly less common in ASA subjects
PMID 21902288 · one of two readings recorded this
tinnitus
unclear
There was a reduction in the risk of headache from ASA and there were non-significant increases in tinnitus and non-GI bleeding
PMID 21902288 · one of two readings recorded this
extra UGIB cases associated with LDA use in RCTs
increases
The mean number of extra UGIB cases associated with LDA use in the RCTs was 1.2 per 1000 patients per year (95% CI 0.7 to 1.8)
PMID 23516680 · one of two readings recorded this
number needed to harm for UGIB, observational studies
increases
819 (95% CI 617 to 1119) for observational studies
PMID 23516680 · one of two readings recorded this
number needed to harm for UGIB, RCTs
increases
The number needed to harm was 816 (95% CI 560 to 1500) for RCTs
PMID 23516680 · one of two readings recorded this
upper gastrointestinal bleeding (UGIB) risk, observational studies
increases
UGIB risk was most pronounced in observational studies (OR 3.1 [95% CI 2.5 to 3.7])
PMID 23516680 · one of two readings recorded this
upper gastrointestinal bleeding (UGIB) risk, pooled odds ratio of RCTs of low-dose acetylsalicylic acid versus placebo
increases, OR 1.5 [95% CI 1.2 to 1.8]
Not recorded as a finding: this platform holds no node for the endpoint
Meta-analysis of RCT data showed that LDA use was associated with a 50% increase in UGIB risk (OR 1.5 [95% CI 1.2 to 1.8]).
PMID 23516680 · one of two readings recorded this
upper gastrointestinal bleeding (UGIB) risk, RCTs
increases
Meta-analysis of RCT data showed that LDA use was associated with a 50% increase in UGIB risk (OR 1.5 [95% CI 1.2 to 1.8])
PMID 23516680 · one of two readings recorded this
upper gastrointestinal bleeding (UGIB) risk with low-dose aspirin, pooled odds ratio from randomised trials and from observational studies
increases, OR 1.5 (95% CI 1.2 to 1.8) pooled across RCTs
Not recorded as a finding: this platform holds no node for the endpoint
Meta-analysis of RCT data showed that LDA use was associated with a 50% increase in UGIB risk (OR 1.5 [95% CI 1.2 to 1.8]).
PMID 23516680 · one of two readings recorded this
fecal blood loss
decreases
patients receiving cimetidine experienced significantly less blood loss than those receiving placebo (mean ± standard deviation 4.1 ± 0.3 mL/day v. 2.2 ± 0.3 mL/day)
PMID 23687524 · one of two readings recorded this
gastric ulcers
decreases, p = 0.002
Another study reported gastric ulcers, which occurred less frequently in the group receiving famotidine than in the placebo group (p = 0.002)
PMID 23687524 · one of two readings recorded this
gastrointestinal hemorrhage confirmed by endoscopy
decreases, n = 447
patients who received an H2 blocker were significantly less likely to experience gastrointestinal hemorrhage than those who received placebo (n = 2 RCTs, 447 patients, OR 0.07, 95% CI 0.02–0.23; Figure 2)
PMID 23687524 · one of two readings recorded this
gastrointestinal hemorrhage requiring admission to hospital
no effect, p = 0.14
gastrointestinal hemorrhage requiring admission to hospital (relative risk 0.11, 95% CI 0.01–2.01, p = 0.14)
PMID 23687524 · one of two readings recorded this
gastrointestinal hemorrhage requiring blood transfusion
no effect, p = 0.29
gastrointestinal hemorrhage requiring blood transfusion (relative risk 0.20, 95% CI 0.01–4.06, p = 0.29)
PMID 23687524 · one of two readings recorded this
harms reported (not related to H2 blockers)
decreases
In another RCT, fewer harms occurred in the famotidine group than in the placebo group (9 v. 15)
PMID 23687524 · one of two readings recorded this
peptic ulcers
decreases, n = 465
H2 blockers were effective in reducing the incidence of peptic ulcers (n = 3 RCTs, 465 patients, OR 0.21, 95% CI 0.12–0.36)
PMID 23687524 · one of two readings recorded this
peptic ulcers
decreases
The results were unchanged when the meta-analysis was conducted with only the 2 studies that excluded ulcers (OR 0.19, 95% CI 0.11–0.33, I2 = 0%)
PMID 23687524 · one of two readings recorded this
ulcers observed by endoscopy
no effect, p = 0.06
One RCT reported no statistically significant changes observed by endoscopy between the placebo and cimetidine groups (p = 0.06)
PMID 23687524 · one of two readings recorded this
amount of administered drugs
no effect, p = 0.05
the studied groups did not differ significantly in the amount of administered drugs (p > 0.05, the Pearson chi-squared test)
PMID 32959110 · one of two readings recorded this
Aspirin reaction units, Visit 1
decreases, p = 0.001
Aspirin reaction units visit 1 (mean ± SD) | 489.0 ± 73.0a | 488.2 ± 83.0a | 638.3 ± 15.9b | = 0.001
PMID 32959110 · one of two readings recorded this
Aspirin reaction units, Visit 2
decreases, p = 0.001
Aspirin reaction units visit 2 (mean ± SD) | 487.62 ± 77.4a | 460.10 ± 82.3a † | 639.2 ± 16.3b | = 0.001
PMID 32959110 · one of two readings recorded this
BMI, non-dippers vs dippers
unclear, p = 0.04
with a mean ± SD of 31.4 ± 4.4 and 28.6 ± 44.1 (Mann-Whitney U test, p = 0.04)
PMID 32959110 · one of two readings recorded this
BMI, weight, waist and hips
no effect, p = 0.05
did not differ significantly between the studied groups and did not change considerably between Visits 1 and 2 (p > 0.05, the Wilcoxon signed-rank test)
PMID 32959110 · one of two readings recorded this
clinic DBP, change Visit 1 to Visit 2 (Wilcoxon)
decreases, p = 0.0001, n = 56
p (Wilcoxon) | p = 0.004 | p = 0.0001 | p > 0.05
PMID 32959110 · one of two readings recorded this
clinic DBP, change Visit 1 to Visit 2 (Wilcoxon)
decreases, p = 0.004, n = 58
p (Wilcoxon) | p = 0.004 | p = 0.0001 | p > 0.05
PMID 32959110 · one of two readings recorded this
clinic DBP, change Visit 1 to Visit 2 (Wilcoxon)
no effect, p = 0.05, n = 61
p (Wilcoxon) | p = 0.004 | p = 0.0001 | p > 0.05
PMID 32959110 · one of two readings recorded this
clinic DBP change
decreases, n = 56
Although the group receiving ASA in the morning revealed a decrease in the clinic BP (by 2.5/1.7 mmHg), the statistically higher drop was displayed by patients using ASA in the evening (by 5.4/3.8 mmHg)
PMID 32959110 · one of two readings recorded this
clinic DBP change
decreases, n = 58
Although the group receiving ASA in the morning revealed a decrease in the clinic BP (by 2.5/1.7 mmHg), the statistically higher drop was displayed by patients using ASA in the evening (by 5.4/3.8 mmHg)
PMID 32959110 · one of two readings recorded this
clinic DBP
no effect, p = 0.05
Clinic DBP [mm Hg] | Visit 1 | > 0.05 | 88.8 ± 4.0 | 88.8 ± 5.3 | 89.0 ± 5.5
PMID 32959110 · one of two readings recorded this
clinic DBP
decreases, p = 0.05
Visit 2 | < 0.05 | 87.2 ± 4.7 a | 85.0 ± 5.7 b | 87.9 ± 3.0 a
PMID 32959110 · one of two readings recorded this
clinic SBP, change Visit 1 to Visit 2 (Wilcoxon)
decreases, p = 0.0001, n = 56
p (Wilcoxon) | p = 0.0001 | p = 0.0001 | p > 0.05
PMID 32959110 · one of two readings recorded this
clinic SBP, change Visit 1 to Visit 2 (Wilcoxon)
decreases, p = 0.0001, n = 58
p (Wilcoxon) | p = 0.0001 | p = 0.0001 | p > 0.05
PMID 32959110 · one of two readings recorded this
clinic SBP, change Visit 1 to Visit 2 (Wilcoxon)
no effect, p = 0.05, n = 61
p (Wilcoxon) | p = 0.0001 | p = 0.0001 | p > 0.05
PMID 32959110 · one of two readings recorded this
clinic SBP change
decreases, n = 56
Although the group receiving ASA in the morning revealed a decrease in the clinic BP (by 2.5/1.7 mmHg), the statistically higher drop was displayed by patients using ASA in the evening (by 5.4/3.8 mmHg)
PMID 32959110 · one of two readings recorded this
clinic SBP change
decreases, n = 58
Although the group receiving ASA in the morning revealed a decrease in the clinic BP (by 2.5/1.7 mmHg), the statistically higher drop was displayed by patients using ASA in the evening (by 5.4/3.8 mmHg)
PMID 32959110 · one of two readings recorded this
clinic SBP
no effect, p = 0.05
Clinic SBP [mm Hg] | Visit 1 | > 0.05 | 145.5 ± 5.0 | 145.2 ± 6.7 | 145.1 ± 5.2
PMID 32959110 · one of two readings recorded this
clinic SBP
decreases, p = 0.05
Visit 2 | < 0.05 | 143.0 ± 4.1 a | 139.8 ± 5.6 b | 144.2 ± 4.6 a
PMID 32959110 · one of two readings recorded this
DBP 24-h, change Visit 1 to Visit 2 (Wilcoxon)
decreases, p = 0.0001, n = 56
p (Wilcoxon) | p > 0.05 | p = 0.0001 | p > 0.05
PMID 32959110 · one of two readings recorded this
DBP 24-h
no effect, p = 0.05
DBP 24 [mm Hg] | Visit 1 | > 0.05 | 82.6 ± 4.4 | 82.3 ± 4.8 | 83.2 ± 5.1
PMID 32959110 · one of two readings recorded this
DBP 24-h
decreases, p = 0.05
Visit 2 | < 0.05 | 82.3 ± 4.1 a | 78.7 ± 5.9 b | 83.1 ± 5.5 a
PMID 32959110 · one of two readings recorded this
DBP daytime, change Visit 1 to Visit 2 (Wilcoxon)
decreases, p = 0.0001, n = 56
p (Wilcoxon) | p = 0.0048 | p = 0.0001 | p < 0.0001
PMID 32959110 · one of two readings recorded this
DBP daytime, change Visit 1 to Visit 2 (Wilcoxon)
decreases, p = 0.0048, n = 58
p (Wilcoxon) | p = 0.0048 | p = 0.0001 | p < 0.0001
PMID 32959110 · one of two readings recorded this
DBP daytime, change Visit 1 to Visit 2 (Wilcoxon)
decreases, p = 0.0001, n = 61
p (Wilcoxon) | p = 0.0048 | p = 0.0001 | p < 0.0001
PMID 32959110 · one of two readings recorded this
DBP daytime
no effect, p = 0.05
DBP d [mm Hg] | Visit 1 | > 0.05 | 86.5 ± 5.2 | 86.4 ± 5.4 | 86.8 ± 5.1
PMID 32959110 · one of two readings recorded this
DBP daytime
no effect, p = 0.05
Visit 2 | > 0.05 | 84.9 ± 5.2 | 84.3 ± 6.2 | 85.7 ± 5.5
PMID 32959110 · one of two readings recorded this
DBP night, change Visit 1 to Visit 2 (Wilcoxon)
decreases, p = 0.0001, n = 56
p (Wilcoxon) | p > 0.05 | p = 0.0001 | p > 0.05
PMID 32959110 · one of two readings recorded this
DBP night
no effect, p = 0.05
DBPn [mm Hg] | Visit 1 | > 0.05 | 79.5 ± 5.3 | 79.1 ± 4.7 | 79.1 ± 4.9
PMID 32959110 · one of two readings recorded this
DBP night
decreases, p = 0.05
Visit 2 | < 0.05 | 78.4 ± 4.6 a | 74.5 ± 5.3 b | 78.4 ± 5.2 a
PMID 32959110 · one of two readings recorded this
DBP24 change
decreases, n = 56
and in the 24-h BP measurements (SBP24 by 5.5 mmHg, DBP24 by 3.56 mmHg and MAP24 by 4.2 mmHg)
PMID 32959110 · one of two readings recorded this
DBPn change
decreases, n = 56
only a group receiving ASA in the evening for 3 months revealed a significant decrease in the blood pressure at night (SBPn by 5.5 mmHg, DBPn by 4.6 mmHg and MAPn by 4.9 mmHg)
PMID 32959110 · one of two readings recorded this
MAP 24-h, change Visit 1 to Visit 2 (Wilcoxon)
decreases, p = 0.0001, n = 56
p (Wilcoxon) | p > 0.05 | p = 0.0001 | p > 0.05
PMID 32959110 · one of two readings recorded this
MAP 24-h
no effect, p = 0.05
[mm Hg] | Visit 1 | > 0.05 | 100.0 ± 3.9 | 99.7 ± 4.4 | 100.3 ± 4.6
PMID 32959110 · one of two readings recorded this
MAP 24-h
decreases, p = 0.05
Visit 2 | < 0.05 | 99.2 ± 3.6 a | 95.5 ± 5.1 b | 100.2 ± 4.3 a
PMID 32959110 · one of two readings recorded this
MAP daytime, change Visit 1 to Visit 2 (Wilcoxon)
decreases, p = 0.0001
p (Wilcoxon) | p = 0.0001 | p = 0.0001 | p = 0.0001
PMID 32959110 · one of two readings recorded this
MAP daytime
no effect, p = 0.05
MAP d [mm Hg] | Visit 1 | > 0.05 | 104.1 ± 4.5 | 104.1 ± 4.9 | 104.3 ± 4.2
PMID 32959110 · one of two readings recorded this
MAP daytime
no effect, p = 0.05
Visit 2 | > 0.05 | 102.6 ± 4.0 | 101.7 ± 5.2 | 102.4 ± 4.5
PMID 32959110 · one of two readings recorded this
MAP night, change Visit 1 to Visit 2 (Wilcoxon)
decreases, p = 0.0001, n = 56
p (Wilcoxon) | p > 0.05 | p = 0.0001 | p > 0.05
PMID 32959110 · one of two readings recorded this
MAP night
no effect, p = 0.05
MAPn [mm Hg] | Visit 1 | > 0.05 | 94.6 ± 4.2 | 94.6 ± 4.0 | 94.5 ± 4.1
PMID 32959110 · one of two readings recorded this
MAP night
decreases, p = 0.05
Visit 2 | < 0.05 | 94.0 ± 3.8 a | 89.7 ± 4.6 b | 94.2 ± 4.0 a
PMID 32959110 · one of two readings recorded this
MAP24 change
decreases, n = 56
and in the 24-h BP measurements (SBP24 by 5.5 mmHg, DBP24 by 3.56 mmHg and MAP24 by 4.2 mmHg)
PMID 32959110 · one of two readings recorded this
MAPn change
decreases, n = 56
only a group receiving ASA in the evening for 3 months revealed a significant decrease in the blood pressure at night (SBPn by 5.5 mmHg, DBPn by 4.6 mmHg and MAPn by 4.9 mmHg)
PMID 32959110 · one of two readings recorded this
NBPF increase between Visit 1 and Visit 2
increases, n = 56
only the group receiving ASA in the evening experienced a significant increase in the NBPF between Visit 1 and Visit 2 (by mean of 3.5%)
PMID 32959110 · one of two readings recorded this
nocturnal blood pressure fall (NBPF), change Visit 1 to Visit 2 (Wilcoxon)
increases, p = 0.0001, n = 56
p (Wilcoxon) | p = 0.032 | p = 0.0001 | p = 0.0002
PMID 32959110 · one of two readings recorded this
nocturnal blood pressure fall (NBPF), change Visit 1 to Visit 2 (Wilcoxon)
decreases, p = 0.032, n = 58
p (Wilcoxon) | p = 0.032 | p = 0.0001 | p = 0.0002
PMID 32959110 · one of two readings recorded this
nocturnal blood pressure fall (NBPF), change Visit 1 to Visit 2 (Wilcoxon)
decreases, p = 0.0002, n = 61
p (Wilcoxon) | p = 0.032 | p = 0.0001 | p = 0.0002
PMID 32959110 · one of two readings recorded this
nocturnal blood pressure fall (NBPF)
no effect, p = 0.05
NBPF [%] | Visit 1 | > 0.05 | 9.0 ± 3.0 | 9.1 ± 2.5 | 9.3 ± 2.8
PMID 32959110 · one of two readings recorded this
nocturnal blood pressure fall (NBPF)
increases, p = 0.05
Visit 2 | < 0.05 | 8.3 ± 2.8 a | 11.8 ± 2.7 b | 7.9 ± 3.6 a
PMID 32959110 · one of two readings recorded this
number of dippers
increases, n = 56
significantly increase the number of dippers in this group—nearly threefold, from 14 patients at Visit 1 to 39 patients at Visit 2
PMID 32959110 · one of two readings recorded this
number of dippers
decreases, n = 58
In the case of the group with morning ASA administration, a decrease in patients identified as dippers was observed—from 22 at Visit 1 to only 16 at Visit 2
PMID 32959110 · one of two readings recorded this
SBP 24-h, change Visit 1 to Visit 2 (Wilcoxon)
decreases, p = 0.0001, n = 56
p (Wilcoxon) | p > 0.05 | p = 0.0001 | p > 0.05
PMID 32959110 · one of two readings recorded this
SBP 24-h
no effect, p = 0.05
SBP 24 [mm Hg] | Visit 1 | > 0.05 | 134.6 ± 6.2 | 134.4 ± 6.8 | 134.6 ± 6.3
PMID 32959110 · one of two readings recorded this
SBP 24-h
decreases, p = 0.05
Visit 2 | < 0.05 | 132.8 ± 5.7 a | 128.9 ± 5.8 b | 134.2 ± 4.9 a
PMID 32959110 · one of two readings recorded this
SBP daytime, change Visit 1 to Visit 2 (Wilcoxon)
decreases, p = 0.0001, n = 56
p (Wilcoxon) | p = 0.0014 | p = 0.0001 | p = 0.0001
PMID 32959110 · one of two readings recorded this
SBP daytime, change Visit 1 to Visit 2 (Wilcoxon)
decreases, p = 0.0014, n = 58
p (Wilcoxon) | p = 0.0014 | p = 0.0001 | p = 0.0001
PMID 32959110 · one of two readings recorded this
SBP daytime, change Visit 1 to Visit 2 (Wilcoxon)
decreases, p = 0.0001, n = 61
p (Wilcoxon) | p = 0.0014 | p = 0.0001 | p = 0.0001
PMID 32959110 · one of two readings recorded this
SBP daytime
no effect, p = 0.05
SBP d [mm Hg] | Visit 1 | > 0.05 | 139.1 ± 6.5 | 139.4 ± 7.2 | 139.2 ± 6.1
PMID 32959110 · one of two readings recorded this
SBP daytime
no effect, p = 0.05
Visit 2 | > 0.05 | 137.9 ± 5.5 | 136.5 ± 6.7 | 137.8 ± 5.2
PMID 32959110 · one of two readings recorded this
SBP night, change Visit 1 to Visit 2 (Wilcoxon)
decreases, p = 0.0001, n = 56
p (Wilcoxon) | p > 0.05 | p = 0.0001 | p < 0.05
PMID 32959110 · one of two readings recorded this
SBP night, change Visit 1 to Visit 2 (Wilcoxon)
no effect, p = 0.05, n = 58
p (Wilcoxon) | p > 0.05 | p = 0.0001 | p < 0.05
PMID 32959110 · one of two readings recorded this
SBP night, change Visit 1 to Visit 2 (Wilcoxon)
unclear, p = 0.05, n = 61
p (Wilcoxon) | p > 0.05 | p = 0.0001 | p < 0.05
PMID 32959110 · one of two readings recorded this
SBP night
no effect, p = 0.05
SBPn [mm Hg] | Visit 1 | > 0.05 | 125.7 ± 7.3 | 125.6 ± 7.0 | 125.2 ± 6.8
PMID 32959110 · one of two readings recorded this
SBP night
decreases, p = 0.05
Visit 2 | < 0.05 | 125.2 ± 7.0 a | 120.1 ± 6.9 b | 125.7 ± 6.6 a
PMID 32959110 · one of two readings recorded this
SBP24 change
decreases, n = 56
and in the 24-h BP measurements (SBP24 by 5.5 mmHg, DBP24 by 3.56 mmHg and MAP24 by 4.2 mmHg)
PMID 32959110 · one of two readings recorded this
SBPn change
decreases, n = 56
only a group receiving ASA in the evening for 3 months revealed a significant decrease in the blood pressure at night (SBPn by 5.5 mmHg, DBPn by 4.6 mmHg and MAPn by 4.9 mmHg)
PMID 32959110 · one of two readings recorded this
uric acid concentration
increases, n = 56
uric acid, which concentration at Visit 2 was increased in the group receiving ASA in the evening when compared with that at Visit 1
PMID 32959110 · one of two readings recorded this
all adverse events of any kind, aspirin fast-release tablets versus placebo
decreases
Not recorded as a finding: node adverse-reaction-incidence-ungraded requires events attributed to the study product; all-cause AEs of any kind are not that, and the formulation is fast-release rather than aspirin generally
For subjects on aspirin FR, we found that they had a significantly decreased risk of 35% of all AEs compared to those on placebo.
PMID 37603157 · one of two readings recorded this
all adverse events of any kind, aspirin FR versus placebo
decreases, significantly decreased risk of 35%
Not recorded as a finding: No fitting node: the only adverse-event nodes are an oral supplement event node and a drug-attributed reaction node; all-cause AEs of a drug trial match neither.
For subjects on aspirin FR, we found that they had a significantly decreased risk of 35% of all AEs compared to those on placebo.
PMID 37603157 · one of two readings recorded this
all AEs
decreases
Aspirin FR vs. placebo | 14.4 (98/681) | 20.4 (70/343) | 0.65 [0.48, 0.90]
PMID 37603157 · one of two readings recorded this
all AEs
no effect
Aspirin mono (plain only, w/o FR) vs. placebo | 13.5 (377/2794)/ | 13.6 (242/1773) | 1.11 [0.93, 1.33]
PMID 37603157 · one of two readings recorded this
all AEs
no effect
All AEs | Aspirin mono vs. placebo | 14.1 (611/4346) | 14.4 (404/2802) | 1.05 [0.91, 1.20]
PMID 37603157 · one of two readings recorded this
all AEs
no effect
Aspirin + PSE vs. placebo | 11.3 (81/716) | 10.2 (37/363) | 1.23 [0.82, 1.86]
PMID 37603157 · one of two readings recorded this
all AEs
no effect
Aspirin mono (plain only, w/o FR) vs. aspirin FR | 14.7 (62/421) | 15.4 (68/441) | 0.93 [0.64, 1.36]
PMID 37603157 · one of two readings recorded this
all GI AEs
no effect
Aspirin FR vs. placebo | 5.9 (40/681) | 8.7 (30/343) | 0.65 [0.41, 1.03]
PMID 37603157 · one of two readings recorded this
all GI AEs
no effect
Aspirin mono (plain only, w/o FR) vs. placebo | 3.9 (108/2794) | 4.1 (73/1773) | 0.97 [0.72, 1.30]
PMID 37603157 · one of two readings recorded this
all GI AEs
no effect
All GI AEs | Aspirin mono vs. placebo | 5.5 (238/4346) | 6.1 (171/2802) | 1.00 [0.81, 1.23]
PMID 37603157 · one of two readings recorded this
all GI AEs
no effect
Aspirin + PSE vs. placebo | 3.5 (25/716) | 3.9 (14/363) | 1.04 [0.53, 2.05]
PMID 37603157 · one of two readings recorded this
all GI AEs
no effect
Aspirin mono (plain only, w/o FR) vs. aspirin FR | 4.8 (20/421) | 5.4 (24/441) | 0.87 [0.47, 1.61]
PMID 37603157 · one of two readings recorded this
drug-related all adverse events, aspirin mono (all galenic formulations, alone or combined with vitamin C, caffeine, calcium) versus placebo
increases, significantly higher risk of 34% and 43% (aspirin mono; aspirin mono plain only)
Not recorded as a finding: The aspirin mono arm contains combination products absent from the placebo comparator, so the contrast does not isolate aspirin.
For drug-related all AEs, subjects on aspirin mono and subjects on aspirin mono (plain only, w/o FR) had a signicantly higher risk of 34% and 43%, respectively, than those on placebo.
PMID 37603157 · one of two readings recorded this
drug-related all AEs
All AEs | 125 (9.44) | 236 (6.09) | 361 (6.94) | 24 (5.14) | 21 (5.83) | 45 (5.44) | 115 (11.20) | 126 (6.10) | 241 (7.80) | 2 (2.70) | 12 (1.66) | 14 (1.76) | 239 (7.33)
PMID 37603157 · one of two readings recorded this
drug-related all AEs
All AEs | 0 (0.00) | 32 (3.00) | 32 (3.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 20 (4.40) | 20 (4.40) | 0 (0.00) | 12 (1.97) | 12 (1.97) | 22 (6.13)
PMID 37603157 · one of two readings recorded this
drug-related all AEs
All AEs | 16 (2.87) | 57 (11.35) | 73 (6.89) | 5 (4.63) | 0 (0.00) | 5 (4.63) | 6 (2.20) | 8 (4.91) | 14 (3.21) | 2 (2.70) | 0 (0.00) | 2 (1.74) | 49 (17.44)
PMID 37603157 · one of two readings recorded this
drug-related all AEs
All AEs | 96 (35.26) | 1 (0.36) | 97 (17.57) | 5 (3.05) | 12 (7.27) | 17 (5.17) | 96 (35.29) | 0 (0.00) | 96 (20.08) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 75 (13.07)
PMID 37603157 · one of two readings recorded this
drug-related all AEs
decreases
Aspirin FR vs. placebob | 1.9 (13/681) | 4.7 (16/343) | 0.39 [0.20, 0.79]
PMID 37603157 · one of two readings recorded this
drug-related all AEs
increases
Aspirin mono (plain only, w/o FR) vs. placebo | 8.4 (235/2794) | 7.7 (137/1773) | 1.43 [1.13, 1.80]
PMID 37603157 · one of two readings recorded this
drug-related all AEs
increases
All AEs | Aspirin mono vs. placeboa | 7.8 (337/4346) | 7.7 (216/2802) | 1.34 [1.11, 1.62]
PMID 37603157 · one of two readings recorded this
drug-related all AEs
no effect
Aspirin + PSE vs. placebo | 5.7 (41/716) | 5.8 (21/363) | 1.12[0.65, 1.94]
PMID 37603157 · one of two readings recorded this
drug-related all AEs
no effect
Aspirin mono (plain only, w/o FR) vs. aspirin FRb | 3.0 (12/403) | 3.0(12/406) | 1.01 [0.45, 2.28]
PMID 37603157 · one of two readings recorded this
drug-related all GI AEs
All GI AEs | 16 (1.21) | 140 (3.61) | 156 (3.00) | 11 (2.36) | 5 (1.39) | 16 (1.93) | 14 (1.36) | 60 (2.91) | 74 (2.39) | 1 (1.35) | 6 (0.83) | 7 (0.88) | 116 (3.56)
PMID 37603157 · one of two readings recorded this
drug-related all GI AEs
All GI AEs | 0 (0.00) | 14 (1.31) | 14 (1.31) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 8 (1.76) | 8 (1.76) | 0 (0.00) | 6 (0.98) | 6 (0.98) | 7 (1.95)
PMID 37603157 · one of two readings recorded this
drug-related all GI AEs
All GI AEs | 5 (0.90) | 50 (9.96) | 55 (5.19) | 2 (1.85) | 0 (0.00) | 2 (1.85) | 3 (1.10) | 6 (3.68) | 9 (2.06) | 1 (1.35) | 0 (0.00) | 1 (0.87) | 45 (16.01)
PMID 37603157 · one of two readings recorded this
drug-related all GI AEs
All GI AEs | 3 (1.10) | 1 (0.36) | 4 (0.72) | 2 (1.22) | 4 (2.42) | 6 (0.74) | 3 (1.10) | 0 (0.00) | 3 (0.63) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 13 (2.26)
PMID 37603157 · one of two readings recorded this
drug-related all GI AEs
no effect
Aspirin FR vs. placebob | 1.0 (7/681) | 2.3 (8/343) | 0.43 [0.17, 1.13]
PMID 37603157 · one of two readings recorded this
drug-related all GI AEs
no effect
Aspirin mono (plain only, w/o FR) vs. placebo | 2.6 (72/2794) | 2.4 (43/1773) | 1.14 [0.78, 1.67]
PMID 37603157 · one of two readings recorded this
drug-related all GI AEs
no effect
All GI AEs | Aspirin mono vs. placeboa | 3.5 (150/4346) | 3.9 (109/2802) | 1.14 [0.88, 1.48]
PMID 37603157 · one of two readings recorded this
drug-related all GI AEs
no effect
Aspirin + PSE vs. placebo | 2.1 (15/716) | 3.0 (11/363) | 0.83 [0.37, 1.87]
PMID 37603157 · one of two readings recorded this
drug-related all GI AEs
no effect
Aspirin mono (plain only, w/o FR) vs. aspirin FRb | 2.0 (8/403) | 1.5 (6/406) | 1.35 [0.46, 3.92]
PMID 37603157 · one of two readings recorded this
drug-related dyspepsia
Dyspepsia | 5 (0.38) | 52 (1.34) | 57 (1.10) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 5 (0.49) | 16 (0.78) | 21 (0.68) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 44 (1.35)
PMID 37603157 · one of two readings recorded this
drug-related dyspepsia
Dyspepsia | 0 (0.00) | 28 (5.58) | 28 (2.64) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 29 (10.32)
PMID 37603157 · one of two readings recorded this
drug-related dyspepsia
Dyspepsia | 3 (1.10) | 1 (0.36) | 4 (0.72) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 3 (1.10) | 0 (0.00) | 3 (0.63) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 4 (0.70)
PMID 37603157 · one of two readings recorded this
drug-related dyspepsia
no effect
Aspirin FR vs. placebob | 0.1 (1/681) | 0.3 (1/343) | 0.50 [0.04, 6.75]c
PMID 37603157 · one of two readings recorded this
drug-related dyspepsia
no effect
Aspirin mono (plain only, w/o FR) vs. placebo | 0.8 (22/2794) | 0.5 (8/1773) | 1.98 [0.88, 4.46]
PMID 37603157 · one of two readings recorded this
drug-related dyspepsia
no effect
Dyspepsia | Aspirin mono vs. placeboa | 1.3 (58/4346) | 1.6 (45/2802) | 1.24 [0.82, 1.88]
PMID 37603157 · one of two readings recorded this
drug-related dyspepsia
no effect
Aspirin + PSE vs. placebo | 0.1 (1/716) | 0.8 (3/363) | 0.32 [0.02, 4.91]
PMID 37603157 · one of two readings recorded this
drug-related dyspepsia
no effect
Aspirin mono (plain only, w/o FR) vs. aspirin FRb | 0.2 (1/403) | 0.2 (1/406) | 1.01 [0.06, 16.20]c
PMID 37603157 · one of two readings recorded this
drug-related GI bleeding
no effect
GI bleeding | Aspirin mono vs. placeboa | 0.0 (1/4346) | 0.1 (3/2802) | 0.23 [0.03, 1.70]
PMID 37603157 · one of two readings recorded this
drug-related minor GI AEs
Minor GI AEs | 6 (0.45) | 58 (1.50) | 64 (1.23) | 2 (0.43) | 3 (0.83) | 5 (0.60) | 6 (0.58) | 32 (1.55) | 38 (1.23) | 0 (0.00) | 6 (0.83) | 6 (0.75) | 49 (1.50)
PMID 37603157 · one of two readings recorded this
drug-related minor GI AEs
Minor GI AEs | 0 (0.00) | 14 (1.31) | 14 (1.31) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 8 (1.76) | 8 (1.76) | 0 (0.00) | 6 (0.98) | 6 (0.98) | 7 (1.95)
PMID 37603157 · one of two readings recorded this
drug-related minor GI AEs
Minor GI AEs | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 3 (1.82) | 3 (0.91) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 5 (0.87)
PMID 37603157 · one of two readings recorded this
drug-related minor GI AEs
no effect
Aspirin FR vs. placebob | 1.0 (7/681) | 2.3 (8/343) | 0.43 [0.17, 1.13]
PMID 37603157 · one of two readings recorded this
drug-related minor GI AEs
no effect
Aspirin mono (plain only, w/o FR) vs. placebo | 1.4 (38/2794) | 1.5 (26/1773) | 0.93 [0.57, 1.51]
PMID 37603157 · one of two readings recorded this
drug-related minor GI AEs
no effect
Minor GI AEs | Aspirin mono vs. placeboa | 1.4 (62/4346) | 1.6 (45/2802) | 0.93 [0.63, 1.38]
PMID 37603157 · one of two readings recorded this
drug-related minor GI AEs
no effect
Aspirin + PSE vs. placebo | 0.7 (5/716) | 1.7 (6/363) | 0.47 [0.14, 1.56]
PMID 37603157 · one of two readings recorded this
drug-related minor GI AEs
no effect
Aspirin mono (plain only, w/o FR) vs. aspirin FRb | 2.0 (8/403) | 1.5 (6/406) | 1.35 [0.46, 3.92]
PMID 37603157 · one of two readings recorded this
drug-unrelated all AEs
All AEs | 56 (4.23) | 285 (7.35) | 341 (6.56) | 33 (7.07) | 20 (5.56) | 53 (6.41) | 38 (3.70) | 129 (6.25) | 167 (5.40) | 9 (12.16) | 89 (12.33) | 98 (12.31) | 227 (6.97)
PMID 37603157 · one of two readings recorded this
drug-unrelated all AEs
All AEs | 0 (0.00) | 129 (12.11) | 129 (12.11) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 54 (11.87) | 54 (11.87) | 0 (0.00) | 75 (12.30) | 75 (12.30) | 52 (14.48)
PMID 37603157 · one of two readings recorded this
drug-unrelated all AEs
All AEs | 28 (5.03) | 59 (11.75) | 87 (8.22) | 12 (11.11) | 0 (0.00) | 12 (11.11) | 10 (3.66) | 32 (19.63) | 42 (9.63) | 9 (12.16) | 1 (2.44) | 10 (8.70) | 47 (16.73)
PMID 37603157 · one of two readings recorded this
drug-unrelated all AEs
All AEs | 3 (1.10) | 14 (5.00) | 17 (3.08) | 3 (1.83) | 5 (3.03) | 8 (2.43) | 3 (1.10) | 1 (0.49) | 4 (0.84) | 0 (0.00) | 13 (18.31) | 13 (18.31) | 21 (3.66)
PMID 37603157 · one of two readings recorded this
drug-unrelated all GI AEs
All GI AEs | 8 (0.60) | 96 (2.48) | 104 (2.00) | 6 (1.28) | 5 (1.39) | 11 (1.33) | 6 (0.58) | 36 (1.74) | 42 (1.36) | 2 (2.70) | 34 (4.71) | 36 (4.52) | 67 (2.06)
PMID 37603157 · one of two readings recorded this
drug-unrelated all GI AEs
All GI AEs | 0 (0.00) | 43 (4.04) | 43 (4.04) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 12 (2.64) | 12 (2.64) | 0 (0.00) | 31 (5.08) | 31 (5.08) | 25 (6.96)
PMID 37603157 · one of two readings recorded this
drug-unrelated all GI AEs
All GI AEs | 3 (0.54) | 21 (4.18) | 24 (2.27) | 1 (0.93) | 0 (0.00) | 1 (0.93) | 1 (0.37) | 9 (5.52) | 10 (2.29) | 2 (2.70) | 0 (0.00) | 2 (1.74) | 10 (3.56)
PMID 37603157 · one of two readings recorded this
drug-unrelated all GI AEs
All GI AEs | 0 (0.00) | 4 (1.43) | 4 (0.72) | 2 (1.22) | 2 (1.21) | 4 (1.22) | 0 (0.00) | 1 (0.49) | 1 (0.21) | 0 (0.00) | 3 (4.23) | 3 (4.23) | 5 (0.87)
PMID 37603157 · one of two readings recorded this
drug-unrelated dyspepsia
Dyspepsia | 0 (0.00) | 11 (0.28) | 11 (0.21) | 1 (0.21) | 0 (0.00) | 1 (0.12) | 0 (0.00) | 1 (0.05) | 1 (0.03) | 0 (0.00) | 1 (0.14) | 1 (0.13) | 4 (0.12)
PMID 37603157 · one of two readings recorded this
drug-unrelated dyspepsia
Dyspepsia | 0 (0.00) | 1 (0.09) | 1 (0.09) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 1 (0.16) | 1 (0.16) | 1 (0.28)
PMID 37603157 · one of two readings recorded this
drug-unrelated dyspepsia
Dyspepsia | 0 (0.00) | 8 (1.59) | 8 (0.76) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 3 (1.07)
PMID 37603157 · one of two readings recorded this
drug-unrelated minor GI AEs
Minor GI AEs | 3 (0.23) | 58 (1.50) | 61 (1.17) | 2 (0.43) | 3 (0.83) | 5 (0.60) | 2 (0.19) | 22 (1.07) | 24 (0.78) | 1 (1.35) | 26 (3.60) | 27 (3.39) | 46 (1.41)
PMID 37603157 · one of two readings recorded this
drug-unrelated minor GI AEs
Minor GI AEs | 0 (0.00) | 32 (3.00) | 32 (3.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 8 (1.76) | 8 (1.76) | 0 (0.00) | 24 (3.93) | 24 (3.93) | 20 (5.57)
PMID 37603157 · one of two readings recorded this
drug-unrelated minor GI AEs
Minor GI AEs | 1 (0.18) | 11 (2.19) | 12 (1.13) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 9 (5.52) | 9 (2.06) | 1 (1.35) | 0 (0.00) | 1 (0.87) | 8 (2.85)
PMID 37603157 · one of two readings recorded this
drug-unrelated minor GI AEs
Minor GI AEs | 0 (0.00) | 2 (0.71) | 2 (0.36) | 0 (0.00) | 1 (0.61) | 1 (0.30) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 2 (2.82) | 2 (2.82) | 1 (0.17)
PMID 37603157 · one of two readings recorded this
dyspepsia
no effect
Aspirin FR vs. placebo | 0.3 (2/681) | 0.6 (2/343) | 0.50 [0.08, 3.02]
PMID 37603157 · one of two readings recorded this
dyspepsia
no effect
aspirin mono (plain only, w/o FR) vs. placebo | 0.8 (22/2794) | 0.5 (9/1773) | 1.72 [0.80, 3.71]
PMID 37603157 · one of two readings recorded this
dyspepsia
no effect
Dyspepsia | Aspirin mono vs. placebo | 1.5 (64/4346) | 1.7 (49/2802) | 1.24 [0.83, 1.85]
PMID 37603157 · one of two readings recorded this
dyspepsia
no effect
Aspirin + PSE vs. placebo | 0.3 (2/716) | 0.8 (3/363) | 0.61 [0.07, 5.37]
PMID 37603157 · one of two readings recorded this
dyspepsia
no effect
Aspirin mono (plain only, w/o FR) vs. aspirin FR | 0.2 (1/421) | 0.5 (2/441) | 0.54 [0.05, 5.76]
PMID 37603157 · one of two readings recorded this
GI bleeding
no effect
Aspirin FR vs. placebo | 0.1 (1/681) | 0.3 (1/343) | 0.50 [0.04, 6.75]
PMID 37603157 · one of two readings recorded this
GI bleeding
no effect
Aspirin mono (plain only, w/o FR) vs. placebo | 0.0 (1/2794) | 0.1 (2/1773) | 0.30 [0.04, 2.39]
PMID 37603157 · one of two readings recorded this
GI bleeding
no effect
GI bleeding | Aspirin mono vs. placebo | 0.0 (1/4346) | 0.1 (3/2802) | 0.23 [0.03, 1.70]
PMID 37603157 · one of two readings recorded this
GI bleeding
no effect
Aspirin + PSE vs. placebo | 0.1 (1/716) | 0.6 (2/363) | 0.26 [0.03, 2.23]
PMID 37603157 · one of two readings recorded this
GI bleeding
no effect
Aspirin mono (plain only, w/o FR) vs. aspirin FR | 0.2 (1/421) | 0.2 (1/441) | 1.05 [0.06, 17.08]
PMID 37603157 · one of two readings recorded this
minor GI AEs
no effect
Aspirin FR vs. placebo | 4.7 (32/681/) | 6.7 (23/343) | 0.68 [0.41, 1.15]
PMID 37603157 · one of two readings recorded this
minor GI AEs
no effect
Aspirin mono (plain only, w/o FR) vs. placebo | 2.1 (59/2794) | 2.7 (48/1773) | 0.77 [0.53, 1.13]
PMID 37603157 · one of two readings recorded this
minor GI AEs
no effect
Minor GI AEs | Aspirin mono vs. placebo | 2.7 (118/4346) | 3.2 (89/2802) | 0.81 [0.61, 1.07]
PMID 37603157 · one of two readings recorded this
minor GI AEs
no effect
aspirin + PSE vs. placebo | 1.4 (10/716) | 1.9 (7/363) | 0.79 [0.30, 2.11]
PMID 37603157 · one of two readings recorded this
minor GI AEs
no effect
Aspirin mono (plain only, w/o FR) vs. aspirin FR | 3.8 (16/421) | 4.5 (20/441) | 0.83 [0.42, 1.63]
PMID 37603157 · one of two readings recorded this
subjects with at least 1 AE
Number of subjects with at least 1 AE | 179 (13.52) | 490 (12.64) | 669 (12.86) | 55 (11.78) | 41 (11.39) | 96 (11.61) | 151 (14.70) | 241 (11.68) | 392 (12.68) | 11 (14.86) | 99 (13.71) | 110 (13.82) | 443 (13.59)
PMID 37603157 · one of two readings recorded this
subjects with at least 1 AE
Number of subjects with at least 1 AE | 0 (0.00) | 156 (14.65) | 156 (14.65) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 71 (15.60) | 71 (15.60) | 0 (0.00) | 85 (13.93) | 85 (13.93) | 70 (19.50)
PMID 37603157 · one of two readings recorded this
subjects with at least 1 AE
Number of subjects with at least 1 AE | 44 (7.90) | 105 (20.92) | 149 (14.07) | 16 (14.81) | 0 (0.00) | 16 (14.81) | 16 (5.89) | 36 (22.09) | 52 (11.93) | 11 (14.86) | 1 (2.44) | 12 (10.43) | 90 (32.03)
PMID 37603157 · one of two readings recorded this
subjects with at least 1 AE
Number of subjects with at least 1 AE | 99 (36.40) | 15 (5.36) | 114 (20.65) | 8 (4.88) | 17 (10.30) | 25 (7.60) | 99 (36.40) | 1 (0.49) | 100 (20.91) | 0 (0.00) | 13 (18.31) | 13 (18.31) | 96 (16.72)
PMID 37603157 · one of two readings recorded this
ADC kurtosis
no effect
ADC Kurtosis (-) mean ± SD | 3.38 ± 1.54 | 3.03 ± 0.99 | 3.01 ± 0.99 | 3.00 ± 0.61
PMID 38317255 · one of two readings recorded this
ADC kurtosis
no effect
ADC Kurtosis (-) mean ± SD | 3.38 ± 1.54 | 3.03 ± 0.99 | 3.01 ± 0.99 | 3.00 ± 0.61
PMID 38317255 · one of two readings recorded this
ADC
no effect
ADC (10–3 mm2 / s) mean ± SD | 1.39 ± 0.41 | 1.28 ± 0.43 | 1.40 ± 0.37 | 1.38 ± 0.39
PMID 38317255 · one of two readings recorded this
ADC
no effect
ADC (10–3 mm2 / s) mean ± SD | 1.39 ± 0.41 | 1.28 ± 0.43 | 1.40 ± 0.37 | 1.38 ± 0.39
PMID 38317255 · one of two readings recorded this
additional inflammatory proteins changed in breast tissue before FDR correction
modulates, p = 0.05, n = 25
An additional 17 proteins in breast tissue showed changes after 6 months of ASA with a p < 0.05 although not after FDR correction
PMID 38317255 · one of two readings recorded this
correlation of wash-out rate with VEGF
increases, p = 0.01
The wash-out rate correlated significantly with the potent angiogenic factor VEGF (p < 0.01, Spearman’s r = 0.359)
PMID 38317255 · one of two readings recorded this
IL-7 and IL-13 in abdominal subcutaneous fat before FDR correction
decreases, p = 0.05, n = 25
Levels of IL-7 and IL-13 were lower in abdominal s.c. fat with a p < 0.05 but not after FDR correction
PMID 38317255 · one of two readings recorded this
in vivo breast tissue levels of 92 inflammatory proteins by microdialysis and proximity extension assay, plus breast MRI perfusion wash-in and wash-out and lean tissue fraction, ASA 160 mg/day versus no treatment for 6 months
decreases, 20 of 92 inflammatory proteins decreased in breast tissue after 6 months of ASA
Not recorded as a finding: this platform holds no node for the endpoint
Out of these 92 proteins, 20 showed decreases in breast tissue after 6 months of ASA therapy.
PMID 38317255 · one of two readings recorded this
inflammatory proteins altered in abdominal subcutaneous fat
no effect, n = 25
none of the proteins that were affected in breast tissue were altered in abdominal s.c. fat
PMID 38317255 · one of two readings recorded this
inflammatory proteins decreased in breast tissue after FDR correction
decreases, n = 25
Out of these 92 proteins, 20 showed decreases in breast tissue after 6 months of ASA therapy
PMID 38317255 · one of two readings recorded this
inflammatory proteins in breast tissue and abdominal subcutaneous fat
no effect, n = 24
In the no-treatment group, no changes in protein levels were observed in breast tissue or abdominal s.c. fat after 6 months
PMID 38317255 · one of two readings recorded this
lean tissue fraction (LTF)
no effect
No differences were found in either group, either with or without Gd3+-containing contrast agent
PMID 38317255 · one of two readings recorded this
local breast tissue inflammatory protein levels in microdialysate, 92-protein Olink proximity extension assay, aspirin 160 mg/day versus no treatment for 6 months; also breast perfusion and lean tissue fraction by MRI
decreases, 20 of 92 proteins decreased in breast tissue after FDR correction
Not recorded as a finding: this platform holds no node for the endpoint
Out of these 92 proteins, 20 showed decreases in breast tissue after 6 months of ASA therapy.
PMID 38317255 · one of two readings recorded this
MCP-3 and IL-20 in breast tissue before FDR correction
decreases, n = 24
In the no-treatment group after 6 months, MCP-3 and IL-20 levels were lower in breast tissue
PMID 38317255 · one of two readings recorded this
PD proton density, fibroglandular tissue
no effect
PD (%; fibroglandular, whole breast) | 84 ± 4 | 84 ± 3.9 | 85 ± 3.4 | 85 ± 3.5
PMID 38317255 · one of two readings recorded this
PD proton density, fibroglandular tissue
no effect
PD (%; fibroglandular, whole breast) | 84 ± 4 | 84 ± 3.9 | 85 ± 3.4 | 85 ± 3.5
PMID 38317255 · one of two readings recorded this